Unmet Need Justifies Risks For Pediatric Use Of Antipsychotics, FDA Advisory Committee Says

Panel’s votes on the safety of AstraZeneca’s Seroquel, Lilly’s Zyprexa and Pfizer’s Geodon to treat pediatric schizophrenia and bipolar disorder indicate that the severity of the conditions and need for additional treatments justify the known risks.